{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:25:19Z","timestamp":1780928719240,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L242144"],"award-info":[{"award-number":["L242144"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["F252053"],"award-info":[{"award-number":["F252053"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["CFH 2024-4-5026"],"award-info":[{"award-number":["CFH 2024-4-5026"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20230484372"],"award-info":[{"award-number":["20230484372"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20250484809"],"award-info":[{"award-number":["20250484809"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Elite Scientists Sponsorship Program by CAST","award":["2023QNRC001"],"award-info":[{"award-number":["2023QNRC001"]}]},{"name":"Young Elite Scientists Sponsorship Program by BAST","award":["BYESS2024001"],"award-info":[{"award-number":["BYESS2024001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00464-026-12838-x","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:24:49Z","timestamp":1776788689000},"page":"4692-4701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of adjuvant transarterial chemoembolization on survival in hepatocellular carcinoma with microvascular invasion: a landmark analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Tian-Chen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian-Xin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Gen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Qun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-6474","authenticated-orcid":false,"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"6","key":"12838_CR1","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jhep.2024.06.018","volume":"81","author":"C Fuster-Anglada","year":"2024","unstructured":"Fuster-Anglada C, Mauro E, Ferrer-F\u00e0brega J, Caballol B, Sanduzzi-Zamparelli M, Bruix J et al (2024) Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection. J Hepatol 81(6):995\u20131004","journal-title":"J Hepatol"},{"issue":"4","key":"12838_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12072-025-10802-w","volume":"19","author":"XP Zhang","year":"2025","unstructured":"Zhang XP, Zhang TC, Wu FF, Li ZQ, Xiao ZH, Yu ZT et al (2025) Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China. Hepatol Int 19(4):903\u2013914","journal-title":"Hepatol Int"},{"issue":"10415","key":"12838_CR3","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chen M, Cheng A-L, Kaseb AO, Kudo M, Lee HC et al (2023) Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 402(10415):1835\u20131847","journal-title":"Lancet"},{"issue":"5","key":"12838_CR4","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1097\/HEP.0000000000001233","volume":"82","author":"T Ma","year":"2025","unstructured":"Ma T, Bai X, Zhang Q, Chen W, Huang K, Qian T et al (2025) Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: a randomized, open-label, phase 3 trial. Hepatology 82(5):1112\u20131121","journal-title":"Hepatology"},{"issue":"1","key":"12838_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40880-018-0331-y","volume":"38","author":"W Wei","year":"2018","unstructured":"Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH et al (2018) Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond) 38(1):61","journal-title":"Cancer Commun (Lond)"},{"issue":"9","key":"12838_CR6","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1158\/1078-0432.CCR-17-2899","volume":"24","author":"Z Wang","year":"2018","unstructured":"Wang Z, Ren Z, Chen Y, Hu J, Yang G, Yu L et al (2018) Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res 24(9):2074\u20132081","journal-title":"Clin Cancer Res"},{"issue":"1","key":"12838_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/JS9.0000000000000805","volume":"110","author":"C Xiang","year":"2023","unstructured":"Xiang C, Shen X, Zeng X, Zhang Y, Ma Z, Zhang G et al (2023) Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate-stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study. Int J Surg 110(1):315\u2013323","journal-title":"Int J Surg"},{"issue":"10","key":"12838_CR8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00432-009-0588-2","volume":"135","author":"C Zhong","year":"2009","unstructured":"Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS et al (2009) A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol 135(10):1437\u20131445","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"12838_CR9","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1245\/s10434-015-5008-z","volume":"23","author":"JJ Sun","year":"2016","unstructured":"Sun JJ, Wang K, Zhang CZ, Guo W, Shi J, Cong WM et al (2016) Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann Surg Oncol 23(4):1344\u20131351","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"12838_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00423-025-03663-2","volume":"410","author":"Y Peng","year":"2025","unstructured":"Peng Y, Shen S, Feng YF, Wen ZC, Qin JY, Lu W et al (2025) Prognostic analysis and limited efficacy of adjuvant TACE in hepatocellular carcinoma following hepatectomy: a propensity score-matched study. Langenbecks Arch Surg 410(1):92","journal-title":"Langenbecks Arch Surg"},{"key":"12838_CR11","doi-asserted-by":"publisher","first-page":"175628482097769","DOI":"10.1177\/1756284820977693","volume":"13","author":"L Liang","year":"2020","unstructured":"Liang L, Li C, Diao YK, Jia HD, Xing H, Pawlik TM et al (2020) Survival benefits from adjuvant transcatheter arterial chemoembolization in patients undergoing liver resection for hepatocellular carcinoma: a systematic review and meta-analysis. Therap Adv Gastroenterol 13:1756284820977693","journal-title":"Therap Adv Gastroenterol"},{"key":"12838_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5087","volume":"340","author":"LE L\u00e9vesque","year":"2010","unstructured":"L\u00e9vesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087","journal-title":"BMJ"},{"issue":"13","key":"12838_CR13","doi-asserted-by":"publisher","first-page":"8744","DOI":"10.1245\/s10434-024-16203-x","volume":"31","author":"R Ito","year":"2024","unstructured":"Ito R, Yoshioka R, Yanagisawa N, Ishii S, Sugitani J, Furuya R et al (2024) Survival analysis of conversion surgery in borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma addressing selection and immortal time bias: a retrospective single-center study. Ann Surg Oncol 31(13):8744\u20138755","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"12838_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.47137","volume":"7","author":"S Brodeur","year":"2024","unstructured":"Brodeur S, Chiu YM, Courteau J, Dorais M, Oliver D, Stip E et al (2024) Medication exposure and mortality in patients with schizophrenia. JAMA Netw Open 7(11):e2447137","journal-title":"JAMA Netw Open"},{"issue":"8","key":"12838_CR15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamaoncol.2024.1831","volume":"10","author":"W Fan","year":"2024","unstructured":"Fan W, Zhu B, Chen S, Wu Y, Zhao X, Qiao L et al (2024) Survival in patients with recurrent intermediate-stage hepatocellular carcinoma: Sorafenib plus TACE vs TACE alone randomized clinical trial. JAMA Oncol 10(8):1047\u20131054","journal-title":"JAMA Oncol"},{"issue":"8","key":"12838_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.110102","volume":"51","author":"JP Lu","year":"2025","unstructured":"Lu JP, Feng JK, Zhao Y, Chen B, Li PP, He C et al (2025) Grading risk of microvascular invasion impacts survival in hepatocellular carcinoma patients undergoing adjuvant transarterial chemoembolization: a multicenter study. Eur J Surg Oncol 51(8):110102","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"12838_CR17","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1007\/s12072-020-10111-4","volume":"14","author":"X Sheng","year":"2020","unstructured":"Sheng X, Ji Y, Ren GP, Lu CL, Yun JP, Chen LH et al (2020) A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC. Hepatol Int 14(6):1034\u20131047","journal-title":"Hepatol Int"},{"issue":"10","key":"12838_CR18","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/aje\/kwi307","volume":"162","author":"Z Zheng","year":"2005","unstructured":"Zheng Z, Elham R, Abrahamowicz M, Louise P (2005) Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 162(10):1016\u20131023","journal-title":"Am J Epidemiol"},{"issue":"23","key":"12838_CR19","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","volume":"31","author":"A Giobbie-Hurder","year":"2013","unstructured":"Giobbie-Hurder A, Gelber RD, Regan MM (2013) Challenges of guarantee-time bias. J Clin Oncol 31(23):2963\u20132969","journal-title":"J Clin Oncol"},{"issue":"1","key":"12838_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jhep.2023.09.010","volume":"80","author":"F Colapietro","year":"2024","unstructured":"Colapietro F, Maisonneuve P, Lytvyak E, Beuers U, Verdonk RC, Van Der Meer AJ et al (2024) Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis. J Hepatol 80(1):53\u201361","journal-title":"J Hepatol"},{"issue":"3","key":"12838_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3350\/cmh.2023.0034","volume":"29","author":"YJ Hwang","year":"2023","unstructured":"Hwang YJ, Bae JS, Lee Y, Hur BY, Lee DH, Kim H (2023) Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging. Clin Mol Hepatol 29(3):733\u2013746","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"12838_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.hpb.2021.11.016","volume":"24","author":"ZH Chen","year":"2022","unstructured":"Chen ZH, Zhang XP, Feng JK, Li LQ, Zhang F, Hu YR et al (2022) Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China. HPB (Oxford) 24(7):1063\u20131073","journal-title":"HPB (Oxford)"},{"issue":"4","key":"12838_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1634\/theoncologist.2018-0305","volume":"24","author":"S Liu","year":"2019","unstructured":"Liu S, Li H, Guo L, Zhang B, Zhou B, Zhang W et al (2019) Tumor size affects efficacy of adjuvant transarterial chemoembolization in patients with hepatocellular carcinoma and microvascular invasion. Oncologist 24(4):513\u2013520","journal-title":"Oncologist"},{"issue":"7","key":"12838_CR24","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R, Shen J, Fang W, Tan G et al (2019) Sorafenib plus hepatic arterial infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib alone for hepatocellular carcinoma with portal vein invasion. JAMA Oncol 5(7):953\u2013960","journal-title":"JAMA Oncol"},{"issue":"11","key":"12838_CR25","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.ejso.2019.06.031","volume":"45","author":"ZH Chen","year":"2019","unstructured":"Chen ZH, Zhang XP, Zhou TF, Wang K, Wang H, Chai Z-T et al (2019) Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: a systematic review and meta-analysis. Eur J Surg Oncol 45(11):2188\u20132196","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"12838_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.21037\/hbsn.2018.09.05","volume":"7","author":"H Wang","year":"2018","unstructured":"Wang H, Du PC, Wu MC, Cong WM (2018) Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion. Hepatobiliary Surg Nutr 7(6):418\u2013428","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"3","key":"12838_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jamasurg.2018.4334","volume":"154","author":"XF Xu","year":"2019","unstructured":"Xu XF, Xing H, Han J, Li ZL, Lau WY, Zhou YH et al (2019) Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg 154(3):209\u2013217","journal-title":"JAMA Surg"},{"issue":"16","key":"12838_CR28","doi-asserted-by":"publisher","first-page":"26671","DOI":"10.18632\/oncotarget.15793","volume":"8","author":"Y Tong","year":"2017","unstructured":"Tong Y, Li Z, Liang Y, Yu H, Liang X, Liu H et al (2017) Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? a propensity score analysis. Oncotarget 8(16):26671\u201326678","journal-title":"Oncotarget"},{"issue":"9","key":"12838_CR29","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/lt.20472","volume":"11","author":"TM Pawlik","year":"2005","unstructured":"Pawlik TM, Delman KA, Vauthey J-N, Nagorney DM, Ng IO-L, Ikai I et al (2005) Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 11(9):1086\u20131092","journal-title":"Liver Transpl"},{"issue":"17","key":"12838_CR30","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","volume":"34","author":"KT Brown","year":"2016","unstructured":"Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT et al (2016) Randomized trial of hepatic artery embolization for hepatocellular carcinoma using Doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 34(17):2046\u20132053","journal-title":"J Clin Oncol"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-026-12838-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-026-12838-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-026-12838-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:53:13Z","timestamp":1780926793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-026-12838-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["12838"],"URL":"https:\/\/doi.org\/10.1007\/s00464-026-12838-x","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tian-Chen Zhang, Wei-Li Jia, Yu Cao, Chen Feng, Zhen-Qi Li, Shuai Xu, Yi-Lin Hu, Fan Zhang, Xiong Chen, Nian-Xin Xia, Wen-Chao Zhao, Ming-Gen Hu, Shu-Qun Cheng, Xiu-Ping Zhang, and Rong Liu have no conflicts of interest or financial ties to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}